Novel prime-boost vaccine strategies against HIV-1
- PMID: 31271322
- DOI: 10.1080/14760584.2019.1640117
Novel prime-boost vaccine strategies against HIV-1
Abstract
Introduction: Given the complexities of HIV infection and the HIV genetic heterogeneity, a successful HIV vaccine should elicit broad adaptive and innate immune responses. Vaccine prime-boost platforms may achieve this goal. Several factors including selection of antigen, type of vector, delivery route, dose, adjuvant, boosting regimen, order of vector injection, and intervals between vaccinations influence the outcome. Areas covered: We reviewed the literature on the latest findings of the various prime-boost HIV vaccine clinical trials, with particular emphasis on the most advanced and promising strategies. Expert opinion: Data suggest that heterologous may be better than homologous prime-boost regimens for protection. The most advanced strategies to have reached efficacy trials use either canarypox vector (ALVAC) boosted by adjuvanted gp120 protein or adenovirus (Ad26) vector expressing mosaic antigens boosted by gp140 protein. DNA prime and vectors and/or protein boost regimens are at less advanced development stage. These regimens, while imperfect (efficacy ≥50%), could contribute substantially to the control of HIV epidemics as a part of a comprehensive HIV prevention program. To ensure prompt vaccine access in populations with the greatest need, attention should be given to post-efficacy activities necessary to achieve appropriate uptake and implementation of effective vaccines.
Keywords: ALVAC; Ad26; HIV vaccine; efficacy; envelope protein; immune correlates of risk; mosaic; prime-boost; viral vector.
Similar articles
-
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.J Infect Dis. 2016 Jun 15;213(12):1946-54. doi: 10.1093/infdis/jiw059. Epub 2016 Feb 11. J Infect Dis. 2016. PMID: 26908741 Free PMC article. Clinical Trial.
-
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.PLoS Med. 2020 May 22;17(5):e1003117. doi: 10.1371/journal.pmed.1003117. eCollection 2020 May. PLoS Med. 2020. PMID: 32442195 Free PMC article. Clinical Trial.
-
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.J Virol. 2019 Jan 17;93(3):e01529-18. doi: 10.1128/JVI.01529-18. Print 2019 Feb 1. J Virol. 2019. PMID: 30429343 Free PMC article.
-
New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Expert Rev Vaccines. 2016 Aug;15(8):1015-27. doi: 10.1586/14760584.2016.1158108. Epub 2016 Mar 16. Expert Rev Vaccines. 2016. PMID: 26910195 Free PMC article. Review.
-
Lessons from HIV-1 vaccine efficacy trials.Curr Opin HIV AIDS. 2016 Nov;11(6):607-613. doi: 10.1097/COH.0000000000000312. Curr Opin HIV AIDS. 2016. PMID: 27537673 Review.
Cited by
-
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.Lancet HIV. 2020 Oct;7(10):e688-e698. doi: 10.1016/S2352-3018(20)30229-0. Lancet HIV. 2020. PMID: 33010242 Free PMC article. Clinical Trial.
-
Cytokine Adjuvants IL-7 and IL-15 Improve Humoral Responses of a SHIV LentiDNA Vaccine in Animal Models.Vaccines (Basel). 2022 Mar 17;10(3):461. doi: 10.3390/vaccines10030461. Vaccines (Basel). 2022. PMID: 35335093 Free PMC article.
-
Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice.Front Microbiol. 2023 Mar 17;14:1136664. doi: 10.3389/fmicb.2023.1136664. eCollection 2023. Front Microbiol. 2023. PMID: 37007461 Free PMC article.
-
Vaccine development for emerging infectious diseases.Nat Med. 2021 Apr;27(4):591-600. doi: 10.1038/s41591-021-01301-0. Epub 2021 Apr 12. Nat Med. 2021. PMID: 33846611 Review.
-
Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice.Int J Nanomedicine. 2024 Aug 6;19:8029-8042. doi: 10.2147/IJN.S464720. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39130684 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical